Fig. 6.

Targeting LSECtin-BTN3A3 axis inhibits breast cancer stemness and tumor growth. a WT-Nude mice were injected with 1 × 10⁴ 231-NC cells and treated with 10 µg of BTN3A1-Fc, BTN3A3-Fc or control-IgG intraperitoneally (i.p.) every three days (n = 10 each). The tumor volume was monitored weekly. One of two experiments is shown. b, d, f Immunofluorescent staining of tumor tissues for human CD90 (red) in human xenograft tumors after administration of BTN3A3-Fc or control-IgG i.p. (b), anti-BTN3A3 (5E08) mAb or isotype control mAb i.p. (d) or anti-BTN3A3 (5E08) mAb or isotype control mAb intratumorally (f). One typical region is shown (scale bar = 20 µm). (c) WT-Nude mice were injected with 231-NC cells and treated with 50 µg of anti-BTN3A3 (5E08) mAb or isotype control mAb i.p. every three days (n = 10 each). The tumor volume was monitored weekly. One of two experiments is shown. e WT-Nude mice were injected with 231-NC cells. Mice were divided into two groups with equal tumor volume and treated with 50 µg of anti-BTN3A3 (5E08) mAb or isotype control mAb intratumorally five weeks after injection (n = 5 each). One of three experiments is shown. g WT-Nude mice were injected with MDA-MB-231 cells. Mice were divided into four groups with equal tumor volumes and intratumorally treated with 50 µg of paclitaxel, anti-BTN3A3 (5E08) mAb, isotype control mAb or a combination of paclitaxel and anti-BTN3A3 (5E08) mAb (n = 5 each). One of three experiments is shown. Data are presented as the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 (two-way ANOVA test for a, c, e, g). See also Supplementary information, Fig. S6